New hepatitis C therapy effective, costs less for patients and payers, UF researchers find
Patients who take new oral direct-acting antivirals for hepatitis C have lower risk for developing liver cancer and other health conditions, cost less to insure in the short term, and end up spending less money on their own health care costs overall, a study by University of Florida researchers has found.